Silver Book

Silver Book Fact

Unplanned Hospital Readmissions & Costs Following Sepsis Hospitalizations

Among 187,697 hospital admissions for medical reasons that were associated with an unplanned 30-day readmission,  147,084 had a diagnosis of sepsis, 15,001 had a diagnosis of AMI, 79,480 were diagnosed with heart failure, 54,396 were diagnosed with COPD, and 59,378 were diagnosed with pneumonia.

The estimated mean cost per readmission was highest for sepsis ($10,070) compared with the other diagnoses including COPD ($8,417),  heart failure ($9,051), AMI ($9,424), and pneumonia ($9533).

Proportion and Cost of Unplanned 30-Day Readmissions After Sepsis Compared With Other Medical Conditions. Journal of American Medical Association Web site. http://jamanetwork.com/journals/jama/fullarticle/2598785. Published January 22 2017. Accessed January 27, 2017

Reference

Title
Proportion and Cost of Unplanned 30-Day Readmissions After Sepsis Compared With Other Medical Conditions
Publication
Journal of American Medical Association
Publication Date
Published January 22 2017
Authors
Chang C, Fine M, Yende S, Balakumar V, et al. V
URL
Read Full Resource

Categories

  • Economic Burden

Related Facts

  • Cost of pneumonia and flu more than $40 billion in 2005
    In 2005, pneumonia and influenza combined cost the U.S. $40.2 billion—$34.2 in direct costs and $6 billion in indirect mortality costs.  
  • HAI Annual Cost
    Healthcare-associated infections in US hospitals cost $96–$147 billion annually.  
  • Flu causes close to 1/2 of lost workdays and low productivity in adults 50-64 during flu season
    During influenza season, influenza-like-illness is responsible for 45% of workdays lost and for 49% of low productivity days among working adults aged 50–64 years.  
  • Higher hospitalization costs due to pneumonia
    Medicare beneficiaries hospitalized for pneumonia have $15,682 higher expenses than those without the infection.  
  • Drug resistant infections cost $16.6 – $26 billion to US healthcare system annually
    Drug-resistant infections cost the U.S. healthcare system between $16.6 and $26 billion in extra costs each year.